

Datasheet: BUF035 BATCH NUMBER 168612

| Description: | MYCOPLASMA REMOVAL AGENT |
|---------------|--------------------------|
| Name: | MYCOPLASMA REMOVAL AGENT |
| Format: | Kit |
| Product Type: | Accessory Reagent |
| Quantity: | 5 ml |

Product Details

| Applications | This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> . | | | | | | | |
|-----------------------------------|--|--|------------|----------------------|---------------------|--|--|--|
| | Tissue Culture | • | NO | Not Determined | Suggested Dilution | | | |
| | Where this product has not been tested for use in a particular technique this does not | | | | | | | |
| | necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls. | | | | | | | |
| Approx. Protein Concentrations | 50ug/ml | | | | | | | |
| Product Information | Mycoplasma Removal A activity intended to elimina contaminated cell cultures | ate <i>Myco</i> µ | olasma sp. | and related organisn | ns from potentially | | | |
| Intended Use | MRA is very effective at removing mycoplasma from infected cell cultures. It shows stron anti-mycoplasma activity against many types of mycoplasma including <i>Mycoplasma orale</i> <i>M. arginini</i> , <i>M. hyorhinis</i> and <i>Acholeplasma laidlawii</i> . | | | | - | | | |
| | MRA is also suitable for use after the removal of mycoplasma, to prevent recontamination of the culture with the original mycoplasma, at preventative doses. | | | | | | | |
| | This product can also be used to prevent initial infection of cells in culture by mycoplas | | | | | | | |
| | ne viability or function be used as a substitut | of cells in culture. It e for good cell culture | | | | | | |

| Instructions For Use | MRA is very easy to use, simply requiring incubation for a week after addition to cell cultures contaminated by mycoplasma. | | |
|----------------------|--|--|--|
| | Indications for Use: | | |
| | 1. Add MRA to cell cultures contaminated by mycoplasma at a concentration of 0.5 μ g/ml and incubate for a week. | | |
| | 2. For media replacement or culture transfer (passage), use a medium containing MRA at this same concentration. | | |
| | 3. Transfer the cell cultures several times without MRA and confirm that regrowth of the contaminating mycoplasma has not occurred. | | |
| | If there is a concern about the presence of mycoplasma in serum or trypsin, MRA can be added to the media at a concentration of 0.5 μ g/ml to prevent contamination of the cell cultures exposed to these products. | | |
| | N.B. The recommended concentration for use is 0.5 μ g/ml. The MRA concentration may be raised up to 1 μ g/ml only when the recommended concentration is ineffective in removing the mycoplasma. | | |
| | The cytotoxicity of MRA is low and cell toxicity is rare when used at the recommended concentration. For specific function of any cell, however, it is recommended that the retention of desired cellular characteristics be confirmed after treatment. Please follow this link to view <u>Sample Data</u> . | | |
| References | Ndungu, F.M. <i>et al.</i> (2006) CD4 T cells from malaria-nonexposed individuals respond to the CD36-Binding Domain of <i>Plasmodium falciparum</i> erythrocyte membrane protein-1 via an MHC class II-TCR-independent pathway. <u>J Immunol. 176 (9): 5504-12.</u> Molla Kazemiha, V. <i>et al.</i> (2009) PCR-based detection and eradication of mycoplasmal infections from various mammalian cell lines: a local experience. <u>Cytotechnology. 61 (3):</u> <u>117-24.</u> | | |
| | 3. Entrican, G. <i>et al.</i> (2009) Growing Hybridomas In: Walker, J.M. (eds) The Protein Protocols Handbook. Springer Protocols Handbooks. Humana Press, Totowa, NJ. pp.1887-99. | | |
| | 4. Molla Kazemiha, V. <i>et al.</i> (2011) Efficiency of Plasmocin [™] on various mammalian cell lines infected by mollicutes in comparison with commonly used antibiotics in cell culture: a local experience. <u>Cytotechnology. 63 (6): 609-20.</u> | | |
| | 5. Chang, M.C. <i>et al.</i> (2015) N-Farnesyloxy-norcantharimide and N-farnesyl- | | |
| | norcantharimide inhibit the progression of leukemia and increase survival days in a | | |
| | syngeneic mouse leukemia model. <u>Anticancer Drugs. 26 (5): 508-17.</u> 6. Russell, C.L. <i>et al.</i> (2017) Combined tissue and fluid proteomics with Tandem Mass | | |
| | Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An | | |
| | Alzheimer's Disease case study. <u>Rapid Commun Mass Spectrom. 31 (2): 153-9.</u> | | |

7. Santana-Rivera, Y. *et al.* (2020) Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer

cells. Am J Transl Res. 12 (4): 1275-92.

| 1. Nakai, N. <i>et al.</i> (2000) Detection and elimination of contaminating microorganis transplantable tumors and cell lines. <u>Exp Anim. 49 (4): 309-13.</u> |
|--|
| Store at room temperature. |
| This product should be stored undiluted. |
| This product is photosensitive and should be protected from light. |
| Guaranteed until date of expiry. Please see product label. |
| Material Safety Datasheet documentation #10271 available at: |
| https://www.bio-rad-antibodies.com/SDS/BUF035 |
| 10271 |
| For research purposes only |
| |

Related Products

Recommended Useful Reagents

PROTEUS PROTEIN A MIDI PURIFICATION KIT (PUR003) PROTEUS PROTEIN A MINI PURIFICATION KIT (PUR008) PROTEUS PROTEIN G MIDI PURIFICATION KIT (PUR012) PROTEUS PROTEIN G MINI PURIFICATION KIT (PUR016) MOUSE MONOCLONAL ANTIBODY ISOTYPING TEST KIT (MMT1) RAT MONOCLONAL ANTIBODY ISOTYPING TEST KIT (RMT1)

| North & South | Tel: +1 800 265 7376 | Worldwide | Tel: +44 (0)1865 852 700 | Europe | Tel: +49 (0) 89 8090 95 21 |
|---------------|--------------------------------------|-----------|--------------------------------------|--------|--------------------------------------|
| America | Fax: +1 919 878 3751 | | Fax: +44 (0)1865 852 739 | | Fax: +49 (0) 89 8090 95 50 |
| | Email: antibody_sales_us@bio-rad.com | | Email: antibody_sales_uk@bio-rad.com | | Email: antibody_sales_de@bio-rad.com |

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M417284:230307'

Printed on 26 Jun 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint